Neurocrine Biosciences Inc. (NBIX)
NASDAQ
153.00
+0.43 (+0.28%)
Closed
Aug 24, 2026
Day's Range
151.90154.39
52 wk Range
122.14186.12
Financial Statements - NBIX - Neurocrine Biosciences Inc.
Revenue
2.86B▲ 21.4%
Net Income
478.60M▲ 40.2%Net Margin 16.7%
EBITDA
688.00M▼ 1.9%
Free Cash Flow
748.70M▲ 34.4%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 2.86B | 2.35B | 1.88B | 1.48B | 1.13B | 1.04B |
| Cost of Goods | 52.10M | 34M | 39.70M | 23.20M | 14.30M | 10.10M |
| Gross Profit | 2.80B | 2.32B | 1.84B | 1.46B | 1.11B | 1.03B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 636.50M | 583M | 394.80M | 249M | 207.80M | 327.50M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -21.40M | -61.40M | -58.10M | -28M | -80.60M | -188M |
| Pre Tax Income | 705.40M | 486M | 332.10M | 213.90M | 101.40M | 106.70M |
| Income Tax | 226.80M | 144.70M | 82.40M | 59.40M | 11.80M | -300.60M |
| Net Income | 478.60M | 341.30M | 249.70M | 154.50M | 89.60M | 407.30M |
| EPS Basic | 4.81 | 3.4 | 2.56 | 1.61 | 0.95 | 4.38 |
| EPS Diluted | 4.67 | 3.29 | 2.47 | 1.56 | 0.92 | 4.16 |
| Basic Shares Outstanding | 99.50M | 100.40M | 97.70M | 95.80M | 94.60M | 93.10M |
| Diluted Shares Outstanding | 99.50M | 100.40M | 97.70M | 95.80M | 94.60M | 93.10M |
| Ebit | 636.50M | 612.60M | 336.70M | 221M | 127.20M | 139.50M |
| Ebitda | 688M | 701.10M | 416.10M | 264.60M | 218.70M | 336.10M |
| Net Income Continuous Operations | 478.60M | 341.30M | 249.70M | 154.50M | 89.60M | 407.30M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
